文献速递脑血管病外科神经重症

Shield技术Pipeline栓塞装置治疗颅内动脉瘤:美国初步经验

Pipeline Embolization Device with Shield Technology for Intracranial Aneurysms: An Initial U.S. Experience.
PubMed 文献 · World Neurosurg · 2018-08-01

本文报告一例38岁女性左侧顶叶Spetzler-Martin 4级动静脉畸形伴8个供血动脉瘤及其中1个近期破裂,经球囊辅助弹簧圈栓塞后,对4个M1段大脑中动脉动脉瘤和1个颈内动脉床突上段动脉瘤,在 compassionate use 申请获批后使用2枚Shield技术Pipeline栓塞装置治疗。术后3周因漏服双联抗血小板治疗发生轻微缺血性卒中,3个月随访时神经功能完好且所有动脉瘤闭塞,双联抗血小板治疗已停用。作者认为表面修饰血流导向装置是双联抗血小板治疗高危患者有前景的血管内工具,但该技术能否免除双联抗血小板治疗尚待确定。

要点

  • Shield技术Pipeline装置尚未在美国获批,本例经 compassionate use 申请获批后使用。
  • 术后3周因漏服双联抗血小板治疗发生轻微缺血性卒中,3个月随访神经功能完好且动脉瘤全部闭塞。
  • 表面修饰血流导向装置能否免除双联抗血小板治疗尚待确定。

核心结论

  • 表面修饰以降低血栓性并加速动脉瘤闭塞的血流导向装置,对双联抗血小板治疗并发症高危患者是有前景的血管内工具。
  • 本例是美国最早使用该装置的病例之一,尽管结局良好,该技术能否免除双联抗血小板治疗尚待确定。

研究设计与样本

  • 病例报告:1例38岁女性左侧顶叶Spetzler-Martin 4级动静脉畸形伴8个供血动脉瘤,其中1个近期破裂。
  • 破裂动脉瘤经球囊辅助弹簧圈栓塞治疗后,对4个M1段大脑中动脉动脉瘤和1个颈内动脉床突上段动脉瘤,在 compassionate use 申请获批后使用2枚Shield技术Pipeline栓塞装置治疗。

主要发现

  • 术后3周,患者因漏服处方双联抗血小板治疗发生轻微缺血性卒中。
  • 3个月随访检查时,患者神经功能完好且所有动脉瘤闭塞,双联抗血小板治疗已停用。

关键数值与推荐

  • 4个M1段大脑中动脉动脉瘤和1个颈内动脉床突上段动脉瘤使用2枚Shield技术Pipeline栓塞装置治疗。
  • 术后3周发生轻微缺血性卒中;3个月随访时所有动脉瘤闭塞。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thromboembolic complications remain a major reason for morbidity and mortality after flow diversion, in addition to hemorrhagic complications not limited to the brain predicated on the prolonged need for dual antiplatelet therapy. Surface modification to decrease thrombogenicity and accelerate aneurysm occlusion is a promising alteration to mitigate those risks. The Pipeline embolization device with Shield Technology possesses such characteristics; however, it has not yet been approved in the United States. CASE DESCRIPTION: We present the case of a 38-year-old woman with a Spetzler-Martin grade 4 left parietal arteriovenous malformation with a total of 8 feeding vessel aneurysms and recent rupture of 1 of those aneurysms that was treated with balloon-assisted coil embolization. Four M1-segment middle cerebral artery aneurysms and 1 supraclinoid internal carotid artery aneurysm were treated with 2 Pipeline embolization Shield devices after a compassionate use request was approved. At 3 weeks after the procedure, the patient experienced a minor ischemic stroke after having missed the prescribed dual antiplatelet therapy. At the 3-month follow-up examination, the patient was neurologically intact and all the aneurysms were occluded. Dual antiplatelet therapy was discontinued. CONCLUSIONS: Flow diverters with surface modification to decrease thrombogenicity and accelerate aneurysm occlusion are promising endovascular tools for patients at high risk of complications with dual antiplatelet therapy. The present case represents one of the first cases performed in the United States using such a device. Despite the favorable outcome in the present case, the question of whether such technology obviates the need for dual antiplatelet therapy remains to be determined.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Griessenauer CJ, Goren O, Dalal SS, et al. Pipeline Embolization Device with Shield Technology for Intracranial Aneurysms: An Initial U.S. Experience. World Neurosurg. 2018. PMID: 30075266. doi:10.1016/j.wneu.2018.07.203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。